Company Description
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.
It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder.
In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions.
The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.
The company was incorporated in 2017 and is based in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Adi Zuloff-Shani |
Contact Details
Address: 1220 West 6th Avenue, Suite 101 Vancouver, BC V6H 1A5 Canada | |
| Phone | 973 536 1016 |
| Website | clearmindmedicine.com |
Stock Details
| Ticker Symbol | CMND |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001892500 |
| ISIN Number | CA1850534027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Executive Officer |
| Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA | Chief Financial Officer |
| Prof. Mark Haden M.S.W. | Vice President of Business Development |
| Mylene Touboul | Accounting Manager |
| Adi Varon | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | 6-K | Report of foreign issuer |
| Mar 19, 2025 | 6-K | Report of foreign issuer |
| Mar 18, 2025 | 6-K | Report of foreign issuer |
| Mar 17, 2025 | EFFECT | Notice of Effectiveness |
| Mar 13, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Mar 10, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | EFFECT | Notice of Effectiveness |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | 6-K | Report of foreign issuer |